Compare EOT & CVRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | EOT | CVRX |
|---|---|---|
| Founded | 2009 | 2000 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Bankers/Brokers/Service | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 265.6M | 253.2M |
| IPO Year | N/A | 2021 |
| Metric | EOT | CVRX |
|---|---|---|
| Price | $16.58 | $9.03 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $13.17 |
| AVG Volume (30 Days) | 38.7K | ★ 232.9K |
| Earning Date | 01-01-0001 | 11-05-2025 |
| Dividend Yield | ★ 4.51% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $55,969,000.00 |
| Revenue This Year | N/A | $11.49 |
| Revenue Next Year | N/A | $16.26 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 18.44 |
| 52 Week Low | $14.63 | $4.30 |
| 52 Week High | $18.30 | $18.55 |
| Indicator | EOT | CVRX |
|---|---|---|
| Relative Strength Index (RSI) | 41.47 | 43.50 |
| Support Level | $16.45 | $8.82 |
| Resistance Level | $16.86 | $9.63 |
| Average True Range (ATR) | 0.23 | 0.67 |
| MACD | -0.04 | -0.07 |
| Stochastic Oscillator | 22.83 | 34.29 |
Eaton Vance National Municipal Opportunities Trust is a diversified, closed-end management investment company. The company's investment objective is to provide current income exempt from regular federal income tax and to achieve capital appreciation. The company invests a majority of its assets in debt obligations issued by or on behalf of states, territories, and possessions of the United States, including the District of Columbia, and their political subdivisions, agencies, or instrumentalities, the interest on which is exempt from regular federal income tax.
CVRx Inc is a commercial-stage medical device company focused on developing, manufacturing, and commercializing minimally invasive neuromodulation solutions for patients with cardiovascular diseases. Its proprietary platform technology, Barostim, is designed to leverage the power of the brain to address the imbalance of the Autonomic Nervous System, which causes heart failure and other cardiovascular diseases. Barostim provides Baroreflex Activation Therapy which in turn triggers an autonomic response to the heart. The majority of revenue is derived from the USA market.